Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Iran Biomed J. 2023 Sep 1;27(5):269-79. doi: 10.61186/ibj.27.5.269. Epub 2023 Jul 8.
CD20 is a differentiation-related antigen exclusively expressed on the membrane of B lymphocytes. CD20 amplification is observed in numerous immune-related disorders, making it an ideal target for immunotherapy of hematological malignancies and autoimmune diseases. MAb-based therapies targeting CD20 have a principal role in the treatment of several immune-related disordes and cancers, including CLL. Fc gamma receptors mediate CD20 internalization in hematopoietic cells; therefore, this study aimed to establish non-hematopoietic stable cell lines overexpressing full-length human CD20 antigen as an in vitro model for CD20-related studies.
CD20 gene was cloned into the transfer vector. The lentivirus system was transfected to packaging HEK 293T cells, and the supernatants were harvested. CHO-K1 cells were transduced using recombinant viruses, and a stable cell pool was developed by the antibiotic selection. CD20 expression was confirmed at the mRNA and protein levels.
Simultaneous expression of GFP protein facilitated the detection of CD20-expressing cells. Immunophenotyping analysis of stable clones demonstrated expression of CD20 antigen. In addition, the mean fluorescence intensity was significantly higher in the CD20-CHO-K1 clones than the wild-type CHO-K1 cells.
This study is the first report on using second-generation lentiviral vectors for the establishment of a non-hematopoietic cell-based system, which stably expresses full-length human CD20 antigen. Results of stable CHO cell lines with different levels of CD20 antigen are well suited to be used for CD20-based investigations, including binding and functional assays.
CD20 是一种分化相关抗原,仅表达于 B 淋巴细胞的膜上。在许多免疫相关疾病中观察到 CD20 扩增,使其成为血液恶性肿瘤和自身免疫性疾病免疫治疗的理想靶点。针对 CD20 的单克隆抗体治疗在治疗多种免疫相关疾病和癌症方面发挥着重要作用,包括 CLL。Fcγ 受体介导 CD20 在造血细胞中的内化;因此,本研究旨在建立过表达全长人 CD20 抗原的非造血稳定细胞系,作为 CD20 相关研究的体外模型。
将 CD20 基因克隆到转移载体中。使用慢病毒系统转染包装的 HEK 293T 细胞,并收获上清液。使用重组病毒转导 CHO-K1 细胞,并通过抗生素选择开发稳定的细胞池。在 mRNA 和蛋白水平上确认 CD20 的表达。
GFP 蛋白的同时表达有助于检测表达 CD20 的细胞。稳定克隆的免疫表型分析表明 CD20 抗原的表达。此外,CD20-CHO-K1 克隆的平均荧光强度明显高于野生型 CHO-K1 细胞。
本研究首次报告使用第二代慢病毒载体建立基于非造血细胞的系统,该系统稳定表达全长人 CD20 抗原。具有不同 CD20 抗原水平的稳定 CHO 细胞系的结果非常适合用于基于 CD20 的研究,包括结合和功能测定。